CRDL
Cardiol TherapeuticsCRDL
CRDL
About: Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Employees: 18
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
7,650% more call options, than puts
Call options by funds: $155K | Put options by funds: $2K
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
0.28% more ownership
Funds ownership: 9.17% [Q4 2024] → 9.45% (+0.28%) [Q1 2025]
10% less funds holding
Funds holding: 41 [Q4 2024] → 37 (-4) [Q1 2025]
23% less capital invested
Capital invested by funds: $9.59M [Q4 2024] → $7.43M (-$2.16M) [Q1 2025]
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
516%
upside
Avg. target
$9
516%
upside
High target
$9
516%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Brandon Folkes | 516%upside $9 | Buy Initiated | 2 Jun 2025 |
HC Wainwright & Co. Vernon Bernardino | 516%upside $9 | Buy Reiterated | 16 Apr 2025 |
Financial journalist opinion
Neutral
Newsfile Corp
2 weeks ago
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.
Neutral
Newsfile Corp
2 weeks ago
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on May 28, 2025, at 4:30 p.m. EDT. Cardiol Therapeutics' 2025 AGM When: May 28, 2025, at 4:30 p.m.
Neutral
Newsfile Corp
1 month ago
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D.
Neutral
Zacks Investment Research
1 month ago
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.
Neutral
Newsfile Corp
1 month ago
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.
Neutral
Newsfile Corp
2 months ago
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, with topline data expected in Q2 2025 CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditis Cash and cash equivalents of $30.6 million as of December 31, 2024,to fund operations into Q3 2026 Toronto, Ontario--(Newsfile Corp. - April 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today its year-end 2024 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2024. Both are available under the Company's profile on EDGAR at www.sec.gov, on SEDAR+ at sedarplus.ca and on the Company's website at cardiolrx.com.
Neutral
Newsfile Corp
3 months ago
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST. A replay of the live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).
Positive
Proactive Investors
3 months ago
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new research published in the Journal of the American College of Cardiology: Basic to Translational Science (JACBTS) supports the potential of its cannabidiol-based drug candidate CRD-38 to treat heart failure. The study, conducted by scientists at Tecnológico de Monterrey in collaboration with researchers from the DeBakey Heart and Vascular Center in Houston, found that pharmaceutically manufactured cannabidiol, administered subcutaneously, helped preserve mitochondrial function and calcium handling in a preclinical model of heart failure.
Neutral
Newsfile Corp
3 months ago
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science ("JACBTS"), titled "Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling" (www.jacc.org/doi/abs/10.1016/j.jacbts.2024.12.009). This research was conducted by scientists from Tecnológico de Monterrey who, together with researchers from the DeBakey Heart and Vascular Center in Houston, TX, are collaborating with Cardiol on the development of the Company's proprietary subcutaneous ("SubQ") formulation of cannabidiol, CRD-38, to treat heart failure with preserved ejection fraction.
Positive
Seeking Alpha
3 months ago
Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts
Cardiol Therapeutics' CardiolRx™ shows promise in treating heart conditions, with ongoing clinical trials for pericarditis, myocarditis, and heart failure, and orphan drug status boosting its potential. Despite a 40% stock price decline, the market undervalues Cardiol's pipeline, with upcoming trial data and potential partnerships as catalysts for appreciation. The company is well-funded, with $15.9 million in cash reported as of 9/30/24, sufficient to meet milestones into 2026, and has a market cap of $99 million.
Charts implemented using Lightweight Charts™